Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studies

Soo Ryang Kim, Susumu Imoto, Taisuke Nakajima, Kenji Ando, Keiji Mita, Katsumi Fukuda, Ryo Nishikawa, Yu-ichiro Koma, Toshiyuki Matsuoka, Masatoshi Kudo, Yoshitake Hayashi

We describe a 15-mm scirrhous hepatocellular carcinoma (HCC) in a 60-year-old man with B-type cirrhosis. Ultrasound disclosed a 15-mm hypoechoic nodule in segment 7. Contrast-enhanced US revealed heterogeneous, not diffuse, hypervascularity in the early phase and a defect in the Kupffer phase. Contrast-enhanced computed tomography (CT) revealed a heterogeneous hypervascular nodule in the early phase and a low-density area in the late phase. Magnetic resonance imaging (MRI) revealed iso- to hypointensity at T1 and high intensity at T2-weighted sequences. Contrast-enhanced MRI also revealed a heterogeneous hypervascular nodule in the early phase and washout in the late phase. Super-paramagnetic iron oxide-MRI revealed a hyperintense nodule. CT during hepatic arteriography and CT during arterial portography revealed heterogeneous hyperattenuation and a perfusion defect, respectively. Based on these imaging findings the nodule was diagnosed as a mixed well-differentiated and moderately-differentiated HCC. Histologically, the nodule was moderately-differentiated HCC characterized by typical cytological and structural atypia with dense fibrosis. Immunohistochemically, the nodule was positive for heterochromatin protein 1 and alpha-smooth muscle actin, and negative for cytokeratin 19. From the above findings, the nodule was diagnosed as scirrhous HCC. Clinicians engaged in hepatology should exercise caution with suspected scirrhous HCC when imaging studies reveal atypical findings, as shown in our case on the basis of chronic liver disease.

© 2009 The WJG Press and Baishideng. All rights reserved.

Keywords: Scirrhous hepatocellular carcinoma; Contrast-enhanced computed tomography; Contrast-enhanced magnetic resonance imaging; Contrast-enhanced ultrasound; Computed tomography during hepatic arteriography; Computed tomography during arterial portography; Heterogeneous hypervascularity

INTRODUCTION

According to World Health Organization (WHO) classifications, hepatocellular carcinoma (HCC) with diffuse fibrosis is subclassified as scirrhous-type HCC (SHCC)[1]. Histologically, it is characterized by diffuse fibrosis along the sinusoid-like blood spaces with varying degrees of atrophy of tumor trabeculae. Preoperative images by computed tomography (CT) and magnetic resonance imaging (MRI) are, however,
often misdiagnosed as those of cholangiolocellular carcinoma (CCC), HCC-CCC, and metastatic carcinoma due to heterogeneous enhancement in the early phase and prolonged enhancement in the late phase attributed to abundant fibrous stroma. Moreover, imaging studies for the diagnosis of SHCC, such as contrast-enhanced ultrasound (US), CT during hepatic arteriography (CTA) and CT during arterial portography (CTAP) have so far not been described. Here, we present a case of moderately differentiated SHCC that histologically manifested as typical cytological and structural atypia with dense fibrosis, whereas imaging studies with contrast-enhanced CT, MRI, US, CTA and CTAP revealed a mixed well-differentiated and moderately-differentiated HCC.

CASE REPORT

A 60-year-old man with B-type liver cirrhosis was admitted in November 2007 for further examination of a 15-mm hypoechoic nodule in segment seven (S7). The patient had no history of alcohol, blood transfusion or drug abuse. On admission, physical examination showed no remarkable abnormalities. Hepatitis B virus was positive for surface antigen and for envelope antibody, and negative for envelope antigen (HBcAg). The amount of HBV deoxyribonucleic acid was less than 2.6 log copy/mL. Laboratory studies disclosed the following abnormal values: platelets $5.3 \times 10^4/\mu L$ (normal, 14-34), aspartate aminotransferase 44 IU/L (0-38), alkaline phosphokinase 864 IU/L (115-359), thymol turbidity 7.7 U (0-4), zinc sulfate turbidity test 14.8 U (2-12), and $\gamma$-globulin 29.3 g/dL (10.6-20.5). The levels of tumor markers were as follows: alpha-fetoprotein (AFP) 3.8 ng/mL (< 10), protein induced by vitamin K absence 71 mAU/mL (0-40), CA19-9 39.4 U/mL (0-37), and CEA 4.78 ng/mL (0-5). US disclosed a 15-mm hypoechoic nodule in S7. Contrast-enhanced CT revealed a heterogeneous, not diffuse, hypervascular nodule in the early phase and a low-density area in the late phase (Figure 1A and B). MRI revealed iso- to hypointensity at T1 and high intensity at T2-weighted sequences. Contrast-enhanced MRI revealed a heterogeneous hypervascular nodule in the early phase and washout in the late phase (Figure 2A and B). Super-paramagnetic iron oxide-MRI revealed a hyperintense nodule. Contrast-enhanced US revealed heterogeneous hypervascularity in the early phase and a defect in the Kupffer phase (Figure 3A and B). CTA and CTAP revealed heterogeneous hyperattenuation and a perfusion defect, respectively (Figure 4). Based on these imaging findings, the nodule was diagnosed as a mixed well-differentiated and moderately differentiated HCC. Histologically, the nodule was moderately-differentiated HCC characterized by typical cytological and structural atypia with dense fibrosis (Figure 5A and B). Immunohistochemically, the nodule was positive for heterochromatin protein 1 and alpha-smooth muscle actin ($\alpha$-SMA) (Figure 5C and D), and negative for cytokeratin 19 (CK19). From the above findings, the nodule was diagnosed as SHCC. We conducted radiofrequency ablation for the SHCC and the nodule was completely ablated. Local recurrence has not been observed over a period of 15 mo.

DISCUSSION

The clinical background of SHCC is not significantly different from that of non-SHCC with regard to age, gender, positive rates to hepatitis viruses, AFP levels, Child-Pugh classification, and the stage of tumor-node-metastasis. In both morbidities, over 60% of cases are associated with chronic hepatitis rather than with liver cirrhosis. HCC patients with liver cirrhosis and liver dysfunction tend not to undergo surgery. In our case, resection was not carried out because of poor liver function attributed to liver cirrhosis.

With no clear pathological definition of SHCC, in particular a standard for the degree of the fibrosis for diagnosing the disease, its rate varies between 0.2% and 4.2%. Regarding terminology, SHCC is often confused with “sclerosing hepatic carcinoma” that is used to designate a variety of tumors with sclerotic change and hypercalcemia arising in non-cirrhotic livers. Sclerosing hepatic carcinoma does not, however, constitute a distinct histopathological entity; some of these tumors appear to be HCC, others CCC. Therefore, sclerosing hepatic carcinoma has been deleted from the WHO classification. Kurogi et al. have defined SHCC as a tumor with diffuse fibrous changes in almost the entire area of the largest cross-section of the tumor and a mean fibrotic area of 39% compared with only 4.6%
SHCC is characterized by stellate fibrosis (84%), no encapsulation (absence of capsule) (100%), no necrosis and hemorrhage (100%), intratumoral portal tracts (80%), remarkable lymphocyte infiltration (84%), clear cell change (84%), and hyaline bodies (52%). The number of α-SMA-positive myofibroblast-like cells (activated stellate cells) in the tumor is about three times that in non-SHCC.

SHCC is occasionally misdiagnosed as fibrolamellar carcinoma (FLC) because of the presence of lamellar fibrosis. FLC is common in young adults and usually arises in the liver without any underlying chronic liver disease. Histologically, FLC is characterized by polyhedral, deeply eosinophilic neoplastic hepatocytes with round nuclei and distinct nucleoli, many of which contain intracytoplasmic hyaline globules and distinct pale bodies, and fibrosis arranged in a lamellar fashion around the neoplastic hepatocytes. Conversely, although SHCC occasionally presents with lamellar fibrosis, the cancer cells being different from those of FLC, it is common in older patients with associated chronic hepatitis or liver cirrhosis. Accordingly, it is not difficult to differentiate SHCC from FLC. In our case, the nodule was not diagnosed as FLC, clinically or histologically.

The US pattern was mostly hypoechoic, and contrast-enhanced CT and MRI revealed mostly heterogeneous hypervascularity in the early phase. The most characteristic feature of the imaging studies was prolonged enhancement in the late phase. Incidentally, imaging studies such as contrast-enhanced US, CTA and CTAP have, so far, not been described for use in the diagnosis of SHCC. Misdiagnosis by imaging studies is more frequent in SHCC than non-SHCC. Of 25 cases of SHCC, nine (36%) have been diagnosed as CCC, combined HCC-CCC, and metastatic carcinoma characterized by abundant fibrous stroma, the misdiagnosis being attributed to the prolonged enhancement of the tumor in the late phase and heterogeneous enhancement in the arterial phase on contrast-enhanced CT.

In our case, contrast-enhanced CT, MRI, US revealed heterogeneous hypervascularity in the early phase; the nodule was not misdiagnosed as CCC or HCC-CCC because the imaging findings showed no prolonged enhancement in the late phase. The nodule was misdiagnosed as well-differentiated and moderately-
differentiated HCC on contrast-enhanced CT, MRI and US, which showed heterogeneous hypervascularity in the early phase and washout in the late phase; CTA and CTAP showed heterogeneous hypervascularity in the arterial and perfusion defect in the portal phases. Immunohistochemically, the nodule was negative for CK19 and, therefore, not CCC. Although contrast-enhanced US, CTA and CTAP did not indicate SHCC, these modalities are very effective in showing the heterogeneous vascular component, washout and perfusion defect of the nodule and contribute to precise diagnosis.

Clinicians engaged in hepatology should exercise caution with suspected SHCC when imaging studies reveal atypical findings, as shown in our case on the basis of chronic liver disease.

REFERENCES
1 Hirohashi S, Ishak KG, Kojiro M, Puig PL, Wanless IR, Fischer HP, Theise ND, Sakamoto M, Tsukuma H. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, eds. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000: 159-172
2 Ishak KG, Goodman ZD, Stocker JT. Hepatocellular carcinoma. In: Rosai J, Sobin LH, eds. Tumors of the Liver and Intrahepatic Bile Ducts, 3rd edition. Washington DC: Armed Forces Institute of Pathology, 1999: 199-230
3 Iha H. Clinicopathogical study on scirrhous hepatocellular carcinoma. A study of 12 resected cases. Acta Hepatol Jpn 1994; 28: 855-863
4 Omata M, Peters RL, Tatter D. Sclerosing hepatic carcinoma: relationship to hypercalcemia. Liver 1981; 1: 33-49
5 Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M. Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol 2006; 21: 1470-1477
6 Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinicopathologic features. Cancer 1980; 46: 372-379
7 Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 1988; 19: 784-794